about

our purpose:
precision medicine

TAmiRNA is a biotech company specialized in the discovery and validation of microRNA biomarkers. Our mission is to provide validated diagnostic solutions to patients with serious aging-related illnesses. We aim to improve and prolong patient stability, health and quality of life with increasing age.

our technology:
microRNA signatures

We are specialized in biomarker development using blood-circulating microRNAs – evolutionary conserved regulators of gene expression and cell/tissue function. We develop diagnostic algorithms (“signatures”) based on the logic combination of microRNA levels and clinical parameters.

age_associated_diseases

our focus:
age-associated diseases

TAmiRNA is actively involved in R&D projects in osteoporosis (OP), cardiovascular disease (CVD), liver disease and aging. OP and CVD are multifactorial illnesses. Using microRNA signatures we aim to decode the contributing disease factors on a personalized level, and to use this knowledge for better diagnosis.

TAmiRNA_team_2019

our team

CEO and co-founder

Matthias Hackl graduated in the area of Biotechnology from the University of Natural Resources and Life Sciences Vienna (Boku) in 2012. His studies of microRNA function in mammalian cell lines and model systems of Ageing involved rotations through labs at the University of Georgia and Minnesota in the United States as well as University Bielefeld in Germany. Matthias has won two private company grants for developing applications of PCR and Flow Cytometry based microRNA quantification tools and was honored by the Austrian Association of Molecular Life Sciences and Biotechnology for his achievements during his PhD. He has authored 30 publications and two book chapters in the field of microRNA biology and held a one-year PostDoc position in microRNA-based cell engineering at the Vienna Institute of Biotechnology before joining TAmiRNA. Matthias Hackl is also co-founder of Remute Bio GmbH, founded in 2016.

CFO and co-founder

Otto Kanzler has more than 30 years experience in process- and business development in the biotech industry. Since 2007 he is serving as Management Consultant for production and technology-development for biotech- and pharma- industry, specified for strategic and economic issues. He is a serial entrepreneur having founded and co-founded several companies, all of which are still active – CEO / CFO of Remute Bio GmbH (founded 2016), co-founder and interim CEO / CFO of Phoenestra GmbH (founded 2015), Advisor of DirectSens GmbH (since 2015), co-founder and CFO of Syconium Lactic Acid GmbH (founded 2014),  co-founder and CFO of TAmiRNA GmbH (founded 2012),  co-founder and CEO of Evercyte GmbH und Chorus GmbH, (both founded 2011). Between 1993 and 2007 he was department head at Boehringer Ingelheim Austria, responsible for the economic issues of the industrial biopharmaceutical business. Prior to this he was head of process development for biopharmaceutical processes at Boehringer Ingelheim Austria (1981-1993).

COO

Andreas B. Diendorfer studied molecular biology at the University of Natural Resources and Life Sciences, Vienna, finishing his Masters in 2015. During his PhD studies at the Austrian Centre of Industrial Biotechnology, he worked on RNAi based cell selection systems for antibody production in CHO cell lines. Including his expertise as freelance software developer, he put a strong focus on computational biology to complement his wet-lab studies. Andreas B. Diendorfer is author and co-author of multiple papers and publications about micro-RNA and RNAi with both an in-vitro and in-silico focus. He joined TAmiRNA in 2019 to establish the in-house data analysis of NGS and qPCR data for biomarker discovery. In 2021 he pursued his MBA studies at the WU Executive Academy in Vienna and supports TAmiRNA as Chief Operations Officer and Head of Computational Biology since 2022.

Scientific advisor and co-founder

Johannes Grillari’s research focus is on improving our understanding of the molecular and physiological mechanisms of regeneration, as well as on the impact of cellular senescence on regeneration, specifically in skin and bone. In addition, he is interested in engineering of mammalian cells to establish relevant and standardizable cell model systems and cell factories.

Johannes Grillari has graduated in Biotechnology at the University of Natural Resources and Life Sciences Vienna (BOKU) in Austria, where he also accomplished his PhD in the field of cell aging in 1999. Since then he has founded and is leading the Christian Doppler Laboratory on Biotechnology of Skin Aging at the Department of Biotechnology at BOKU. He has worked as visiting scientist in the lab of Angus Lamond in Dundee, Scotland, in the field of RNA biology. In 2010 he was appointed Associate Professor at BOKU, in 2019 director of the Ludwig Boltzmann Institute of Experimental and Clinical Traumatology, Vienna. He also acted as co-founder in 2011 for Evercyte, a company generating and providing immortalized cells for in vitro toxiciology, biopharmaceutical and cosmetical research and development. In 2013, he co-founded TAmiRNA, a company interested in identifying circulating miRNAs as biomarkers for aging and age-associated diseases, specifically in osteoporosis. He has published more than 140 peer reviewed articles, holds 14 patents and has been invited speaker to more than 130 international conferences and departmental seminars. He has received several awards including the Walter-Doberauer award for aging research.

Scientific advisor and co-founder

Regina Grillari is associate professor for cellular biology since 2008 and has been leading a group focused on cellular immortalization and cell line development for more than 10 years at the Department of Biotechnology, University of Natural Resources and Applied Life Sciences Vienna, Austria. She achieved her PhD in 2000 on immortalization of human cells and recombinant protein expression and was appointed to receive the Prof. Anton Kurir habilitation award in 2009.  In 2012 she received the “Phoenix Award” for successful academic entrepreneurship from the Austrian Ministry of Science and Research and 2015 she achieved third place of the Houska Award of the B&C Holding. Furthermore Regina Grillari has authored and co-authored more than 50 scientific publications and book chapters, 4 patents. In addition she is co-founder and CTO of Evercyte GmbH (est. 2011), co-founder of Phoenestra GmbH (2015) and also co-founder and scientific advisor of Remute Bio GmbH (2016).

advisory board

Scientific advisor and co-founder

Regina Grillari is associate professor for cellular biology since 2008 and has been leading a group focused on cellular immortalization and cell line development for more than 10 years at the Department of Biotechnology, University of Natural Resources and Applied Life Sciences Vienna, Austria. She achieved her PhD in 2000 on immortalization of human cells and recombinant protein expression and was appointed to receive the Prof. Anton Kurir habilitation award in 2009.  In 2012 she received the “Phoenix Award” for successful academic entrepreneurship from the Austrian Ministry of Science and Research and 2015 she achieved third place of the Houska Award of the B&C Holding. Furthermore Regina Grillari has authored and co-authored more than 50 scientific publications and book chapters, 4 patents. In addition she is co-founder and CTO of Evercyte GmbH (est. 2011), co-founder of Phoenestra GmbH (2015) and also co-founder and scientific advisor of Remute Bio GmbH (2016).

Scientific advisor and co-founder

Johannes Grillari’s research focus is on improving our understanding of the molecular and physiological mechanisms of regeneration, as well as on the impact of cellular senescence on regeneration, specifically in skin and bone. In addition, he is interested in engineering of mammalian cells to establish relevant and standardizable cell model systems and cell factories.

Johannes Grillari has graduated in Biotechnology at the University of Natural Resources and Life Sciences Vienna (BOKU) in Austria, where he also accomplished his PhD in the field of cell aging in 1999. Since then he has founded and is leading the Christian Doppler Laboratory on Biotechnology of Skin Aging at the Department of Biotechnology at BOKU. He has worked as visiting scientist in the lab of Angus Lamond in Dundee, Scotland, in the field of RNA biology. In 2010 he was appointed Associate Professor at BOKU, in 2019 director of the Ludwig Boltzmann Institute of Experimental and Clinical Traumatology, Vienna. He also acted as co-founder in 2011 for Evercyte, a company generating and providing immortalized cells for in vitro toxiciology, biopharmaceutical and cosmetical research and development. In 2013, he co-founded TAmiRNA, a company interested in identifying circulating miRNAs as biomarkers for aging and age-associated diseases, specifically in osteoporosis. He has published more than 140 peer reviewed articles, holds 14 patents and has been invited speaker to more than 130 international conferences and departmental seminars. He has received several awards including the Walter-Doberauer award for aging research.

Scientific advisor

Heinz Redl has been the director of the Ludwig Boltzmann Institute for Experimental and Clinical Traumatology from 1998-2019. In his group, Dr. Redl has pioneered research in the field of tissue/bone regeneration and has lead the development of innovative approaches to bone healing and is since the foundation of the Austrian Cluster for Tissue Regeneration in 2016 its coordinator.

Prof. Redl assists in TAmiRNA in the design and conduction of pre-clinical trials.

Scientific advisor

Peter Pietschmann is Deputy Head at the Department of Pathophysiology at the Medical University of Vienna since 2006 after being appointed as Associate Professor in 2002. His group is conducting research on the pathophysiology of bone fragility and the relation of bone strength to gene expression. He has published 169 papers in peer-reviewed journals in the area of Osteoporosis and was honored with several awards. Dr. Pietschmann is currently serving as President of the Austrian Society of Bone and Mineral Research, and former president of the Austrian Society of Geriatrics & Gerontology.

Peter Pietschmann supports TAmiRNA in scientific and strategic decisions in developing novel biomarkers for risk assessment in osteoporosis.

Scientific advisor

As a former professor of the Medical University of Vienna, Prof. Woloszczuk was involved in the development of numerous biochemical biomarkers and diagnostic tests for bone diseases. He co-founded the Biomedica GmbH, which specializes in the development and commercialization of diagnostic products. 

Prof. Woloszczuk supports TAmiRNA in strategic decisions in respect to development and marketing of its novel biomarker tests.

our partners

Biogenity

Biogenity

Collaboration partner including Next-Generation Sequencing (NGS) and bioinformatics analysis tools.

https://biogenity.com/

BioCat

BioCat GmbH

Distribution Partner for Germany.
https://www1.biocat.com/

BioVendor

Biovendor
Distribution Partner for Slovakia, Czech Republic, Scandinavia, Western Europe and North America
www.biovendor.com

Biomedica

Biomedica
Central European Distribution partner
www.bmgrp.com/home/

Summit Pharmaceuticals International Co.

Summit Pharmaceuticals International Co.

Distribution Partner for Japan.

https://www.summitpharma.co.jp

advanceCOR

advanceCOR
Partner in the Eurostars project entitled: ”thrombomiR – a novel microRNA-based platelet function biomarker for personalized anti-thrombotic treatment”.
www.advancecor.de

THP

THP Medical Products
Distribution Partner for Austria, Switzerland and Southern Germany
www.thp.at/

FFG

Die Österreichische Forschungsförderungsgesellschaft FFG
“Basisprogramm” financing of R&D cooperations of TAmiRNA.
www.ffg.at

Vivomicx

Vivomicx
Partner in preclinical drug discovery and  drug development
www.vivomicx.eu

SimplicityBio

SimplicityBio
Partner in biomarker development services.
www.simplicitybio.com

TELLVienna
BOKU

BOKU – VIBT
Partner for assay development and functional in vitro screenings of microRNAs that are associated with age-related disorders.
www.boku.ac.at/vibt.html

Evercyte

Evercyte GmbH
Partner in the application of pre-clinical models for toxicity and efficacy testing of novel drug candidates
www.evercyte.com

GrillariLabs

Grillari Labs
Partner in development of basic research models to gain a better understanding microRNA function in age-related disorders such as Osteoporosis, Cardiovascular Disease or Neurodegenerative Disease
www.grillarilabs.at

Cardiolinc

Cardiolinc
Partner for collaborating on projects and translational research.
www.cardiolinc.org

LBI

Ludwig Boltzmann Institute for Experimental and Clinical Traumatology

www.trauma.lbg.ac.at/de

Austrian Cluster for Tissue Regeneration

Austrian Cluster for Tissue Regeneration

www.tissue-regeneration.at

Innofly

Innofly Management
Supports TAmiRNA in backoffice activities
www.innofly.at

TransformScience

Transform Science
Partner for the implementation of quality driven processes.
www.transform-science.com

DirectSens GmbH

DirectSens GmbH

Inspired by nature – applied in technology

www.directsens.com

Intuitive biosensor for the dairy industry
www.lactosens.com

job offers

passion and motivation

At TAmiRNA we are looking for people passionate about science and who are willing to contribute to a society that is healthier and more stable. We continually seek for best-qualified candidates who want to become part in our collaborative and committed team.

Interested candidates should email a cover letter and resume to karriere(at)tamirna.com

TAmiRNA is searching for a new team member. You are looking for a new Job feel free to apply!

PhD Fellow – click here for more information